Allena Pharmaceuticals to Present at Upcoming Investor Conferences in March

Rhea-AI Summary

Allena Pharmaceuticals (NASDAQ: ALNA) announced participation in two investor conferences in March 2021. The first is Cowen’s 41st Annual Health Care Conference, where CEO Louis Brenner, M.D. will discuss kidney disease on March 3, 2021, at 3:20 p.m. ET. The second is the H.C. Wainwright Global Life Sciences Conference, featuring a pre-recorded corporate overview available on March 9, 2021, at 7:00 a.m. ET. Both events will facilitate one-on-one meetings with management. Allena focuses on first-in-class oral enzyme therapeutics for rare metabolic and kidney disorders.

NEWTON, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will participate in two upcoming investor conferences in March:

Cowen’s 41^st Annual Health Care Conference

• Louis Brenner, M.D., Allena’s President and Chief Executive Officer, will participate in a panel discussion on kidney disease, beginning at 3:20 p.m. ET on Wednesday, March 3, 2021. Management will also be available for one-on-one meetings from Monday, March 1 – Wednesday, March 3, 2021.
  

H.C. Wainwright Global Life Sciences Conference

• Louis Brenner, M.D., Allena’s President and Chief Executive Officer, will pre-record a corporate overview, which will become available for on-demand viewing at 7:00 a.m. ET on Tuesday, March 9, 2021. Management will also be available for one-on-one meetings from Tuesday, March 9 – Wednesday, March 10, 2021.
  

The H.C. Wainwright presentation will be available for on-demand viewing under “Events and Presentations” in the Investors section of the Company’s website at www.allenapharma.com. A replay of the webcast will be available on the Allena website for approximately 30 days.

About Allena Pharmaceuticals
Allena Pharmaceuticals, Inc. is a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena’s lead product candidate, reloxaliase, is currently being evaluated in a pivotal Phase 3 clinical program for the treatment of enteric hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders. Allena is also developing ALLN-346 for the treatment of hyperuricemia in the setting of gout and advanced chronic kidney disease, with Phase 1b multiple-ascending dose and Phase 2 proof-of-concept studies planned for 2021.

Investor Contact
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com

Media Contact
Adam Daley
Berry & Company Public Relations
212-253-8881
adaley@berrypr.com

FAQ

What investor conferences will Allena Pharmaceuticals participate in March 2021?

Allena Pharmaceuticals will participate in Cowen’s 41st Annual Health Care Conference and the H.C. Wainwright Global Life Sciences Conference in March 2021.

When will Allena Pharmaceuticals' CEO speak at the Cowen Conference?

Louis Brenner, M.D., CEO of Allena Pharmaceuticals, will speak on kidney disease at the Cowen Conference on March 3, 2021, at 3:20 p.m. ET.

What date is the H.C. Wainwright presentation for Allena Pharmaceuticals?

The H.C. Wainwright presentation will be available on March 9, 2021, at 7:00 a.m. ET.

How can I view Allena Pharmaceuticals' corporate overview?

The corporate overview from Allena Pharmaceuticals will be available on-demand on their website under 'Events and Presentations' starting March 9, 2021.

What is Allena Pharmaceuticals' lead product candidate?

Allena Pharmaceuticals' lead product candidate is reloxaliase, aimed at treating enteric hyperoxaluria.